Gene therapy using adeno-associated virus (AAV) vectors is currently expanding to broad clinical applications. As the presence of a neutralizing antibody (NAb) against AAV capsids significantly restrains their efficacy, an accurate evaluation of NAb status is crucial for selecting appropriate candidates for gene therapy. Notably, cell-based NAb assays may not be sufficiently sensitive for detecting low-titer NAb, and few assays can evaluate multiple AAV serotypes using a commonly available cell. In this study, we developed a sensitive NAb assay against various AAV serotypes using commonly available HEK293 and Huh-7 cells. We found that adding glucose efficiently enhanced transgene expression across various AAV serotypes without causing cell damage. In addition, by combining a highly sensitive reporter gene, NanoLuc, the necessary dose of AAV vector was significantly reduced. The reduction of AAV dose resulted in the increased sensitivity of NAb detection as low as 100 vector genomes/cell. At the lower vector doses, sensitivity improvement was not observed regardless of serotypes, suggesting the limit of assay sensitivity of the cell-based NAb assay. These findings provide a highly sensitive methodology for assessing NAb titers and offer insights into conditions to attain maximal sensitivity in the cell-based NAb assay.
Get full access to this article
View all access options for this article.
References
1.
DunbarCE, HighKA, JoungJK, et al.Gene therapy comes of age. Science, 2018; 359(6372); doi: 10.1126/science.aan4672
2.
SchulzM, LevyDI, PetropoulosCJ, et al.Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy. Mol Ther, 2023; 31(3):616–630; doi: 10.1016/j.ymthe.2023.01.010
3.
ErlesK, SebökovàP, SchlehoferJR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol, 1999; 59(3):406–411.
4.
LiC, NarkbunnamN, SamulskiRJ, et al.; Joint Outcome Study Investigators. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther, 2012; 19(3):288–294; doi: 10.1038/gt.2011.90
5.
Louis JeuneV, JoergensenJA, HajjarRJ, et al.Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods, 2013; 24(2):59–67; doi: 10.1089/hgtb.2012.243
6.
MingozziF, HighKA. Overcoming the host immune response to adeno-associated virus gene delivery vectors: The race between clearance, tolerance, neutralization, and escape. Annu Rev Virol, 2017; 4(1):511–534; doi: 10.1146/annurev-virology-101416-041936
7.
MingozziF, AnguelaXM, PavaniG, et al.Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med, 2013; 5(194):194ra92; doi: 10.1126/scitranslmed.3005795
8.
MelianiA, BoisgeraultF, FitzpatrickZ, et al.Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. Blood Adv, 2017; 1(23):2019–2031; doi: 10.1182/bloodadvances.2017010181
9.
LeborgneC, BarbonE, AlexanderJM, et al.IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med, 2020; 26(7):1096–1101; doi: 10.1038/s41591-020-0911-7
10.
GorovitsB, FiscellaM, HavertM, et al.Recommendations for the development of cell-based anti-viral vector neutralizing antibody assays. AAPS J, 2020; 22(2):24; doi: 10.1208/s12248-019-0403-1
11.
GorovitsB, AzadehM, BuchlisG, et al.Evaluation of the humoral response to adeno-associated virus-based gene therapy modalities using total antibody assays. AAPS J, 2021; 23(6):108; doi: 10.1208/s12248-021-00628-3
12.
NathwaniAC, DavidoffAM, HanawaH, et al.Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood, 2002; 100(5):1662–1669; doi: 10.1182/blood-2002-02-0589
13.
GuoP, ZhangJ, ChrzanowskiM, et al.Rapid AAV-neutralizing antibody determination with a cell-binding assay. Mol Ther Methods Clin Dev, 2019; 13:40–46; doi: 10.1016/j.omtm.2018.11.007
14.
WangM, CrosbyA, HastieE, et al.Prediction of adeno-associated virus neutralizing antibody activity for clinical application. Gene Ther, 2015; 22(12):984–992; doi: 10.1038/gt.2015.69
15.
MendellJR, ConnollyAM, LehmanKJ, et al.Testing preexisting antibodies prior to AAV gene transfer therapy: Rationale, lessons and future considerations. Mol Ther Methods Clin Dev, 2022; 25:74–83; doi: 10.1016/j.omtm.2022.02.011
16.
MasatE, PavaniG, MingozziF. Humoral immunity to AAV vectors in gene therapy: Challenges and potential solutions. Discov Med, 2013; 15(85):379–389.
17.
MohammadiES, KetnerEA, JohnsDC, et al.Expression of the adenovirus E4 34k oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell line. Nucleic Acids Res, 2004; 32(8):2652–2659; doi: 10.1093/nar/gkh593
18.
MelianiA, LeborgneC, TriffaultS, et al.Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system. Hum Gene Ther Methods, 2015; 26(2):45–53; doi: 10.1089/hgtb.2015.037
19.
ZhengZ, YeJ, LengM, et al.Enhanced sensitivity of neutralizing antibody detection for different AAV serotypes using HeLa cells with overexpressed AAVR. Front Pharmacol, 2023; 14:1188290; doi: 10.3389/fphar.2023.1188290
20.
CalcedoR, ChichesterJA, WilsonJM. Assessment of humoral, innate, and T-cell immune responses to adeno-associated virus vectors. Hum Gene Ther Methods, 2018; 29(2):86–95; doi: 10.1089/hgtb.2018.038
21.
KrotovaK, AslanidiG. Modifiers of adeno-associated virus-mediated gene expression in implication for serotype-universal neutralizing antibody assay. Hum Gene Ther, 2020; 31(19–20):1124–1131; doi: 10.1089/hum.2020.074
22.
BaatartsogtN, KashiwakuraY, HayakawaM, et al.A sensitive and reproducible cell-based assay via secNanoLuc to detect neutralizing antibody against adeno-associated virus vector capsid. Mol Ther Methods Clin Dev, 2021; 22:162–171; doi: 10.1016/j.omtm.2021.06.004
23.
PanY, RohdeM, ZeitlerJ, et al.A sensitive AAV transduction inhibition assay assists evaluation of critical factors for detection and concordance of pre-existing antibodies. Mol Ther Methods Clin Dev, 2023; 31:101126; doi: 10.1016/j.omtm.2023.101126
24.
NaguroI, UmedaT, KobayashiY, et al.ASK3 responds to osmotic stress and regulates blood pressure by suppressing WNK1-SPAK/OSR1 signaling in the kidney. Nat Commun, 2012; 3:1285; doi: 10.1038/ncomms2283
25.
LiF, VijayasankaranN, ShenAY, et al.Cell culture processes for monoclonal antibody production. MAbs, 2010; 2(5):466–479; doi: 10.4161/mabs.2.5.12720
26.
SunZ, ZhouR, LiangS, et al.Hyperosmotic stress in murine hybridoma cells: Effects on antibody transcription, translation, posttranslational processing, and the cell cycle. Biotechnol Prog, 2004; 20(2):576–589; doi: 10.1021/bp0342203
27.
XuWJ, LinY, MiCL, et al.Progress in fed-batch culture for recombinant protein production in CHO cells. Appl Microbiol Biotechnol, 2023; 107(4):1063–1075; doi: 10.1007/s00253-022-12342-x
28.
ShenCF, KamenA. Hyperosmotic pressure on HEK 293 cells during the growth phase, but not the production phase, improves adenovirus production. J Biotechnol, 2012; 157(1):228–236; doi: 10.1016/j.jbiotec.2011.11.016
29.
YuC, TrivediPD, ChaudhuriP, et al.NaCl and KCl mediate log increase in AAV vector particles and infectious titers in a specific/timely manner with the HSV platform. Mol Ther Methods Clin Dev, 2021; 21:1–13; doi: 10.1016/j.omtm.2021.02.015
30.
MizukamiH, MimuroJ, OguraT, et al.Adipose tissue as a novel target for in vivo gene transfer by adeno-associated viral vectors. Hum Gene Ther, 2006; 17(9):921–928; doi: 10.1089/hum.2006.17.921
31.
YagiH, OguraT, MizukamiH, et al.Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector. J Gene Med, 2011; 13(2):114–122; doi: 10.1002/jgm.1543
32.
MimuroJ, MizukamiH, ShimaM, et al.The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals. J Med Virol, 2014; 86(11):1990–1997; doi: 10.1002/jmv.23818
33.
WatanoR, OhmoriT, HishikawaS, et al.Utility of microminipigs for evaluating liver-mediated gene expression in the presence of neutralizing antibody against vector capsid. Gene Ther, 2020; 27(9):427–434; doi: 10.1038/s41434-020-0125-0
34.
HayashiY, SeharaY, WatanoR, et al.Therapeutic strategy for Fabry disease by intravenous administration of adeno-associated virus 9 in a symptomatic mouse model. Hum Gene Ther, 2024; 35(5–6):192–201; doi: 10.1089/hum.2023.106
35.
HoY, KiparissidesA, PistikopoulosEN, et al.Computational approach for understanding and improving GS-NS0 antibody production under hyperosmotic conditions. J Biosci Bioeng, 2012; 113(1):88–98; doi: 10.1016/j.jbiosc.2011.08.022
